Oramed Pharmaceuticals (ORMP) to Release Earnings on Thursday

Oramed Pharmaceuticals (NASDAQ:ORMP) is expected to be issuing its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Oramed Pharmaceuticals Price Performance

ORMP stock opened at $3.57 on Thursday. Oramed Pharmaceuticals has a one year low of $1.82 and a one year high of $3.76. The stock has a market cap of $142.09 million, a price-to-earnings ratio of 2.83 and a beta of 1.31. The company has a fifty day moving average price of $3.42 and a two-hundred day moving average price of $2.86.

Oramed Pharmaceuticals Announces Dividend

The business also recently announced a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were paid a dividend of $0.25 per share. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio (DPR) is currently 19.84%.

Institutional Trading of Oramed Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its holdings in Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 17,510 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Oramed Pharmaceuticals by 4.4% during the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after buying an additional 6,261 shares in the last quarter. HRT Financial LP acquired a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth $131,000. Marshall Wace LLP bought a new stake in shares of Oramed Pharmaceuticals in the fourth quarter valued at about $738,000. Finally, Squarepoint Ops LLC grew its stake in shares of Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 28,406 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.